GLP 1

These conversations include boosting fiber and protein, encouraging more physical activity, managing GI side effects, and discussing the importance of building muscle mass. The issue of alcohol consumption during GLP-1 use also warrants further discussion. Timing of Patient Discussions Dr Neha VyasIdeally, primary care physicians (PCPs) should discuss the risks and benefits of GLP-1 medications […]

Madhusmita Misra, MD, MPH; Sidhartha Pani, MD DISCLOSURES January 27, 2026 GLP-1 receptor agonists (RAs) have transformed the management of type 2 diabetes and obesity by producing substantial weight loss and improving cardiometabolic risk profiles. Despite these benefits, concern remains regarding their effects on skeletal muscle, particularly the reduction in lean body mass observed during therapy. Weight loss is typically accompanied by

Mary Brophy Marcus Jennifer Lynn-Pullman had been taking Wegovy for a few months when she began shivering during a walk on a hot August day. “It was about 85 degrees — I should have been sweating,” said Lynn-Pullman, a 48-year-old dietician from Pennsylvania. A weeklong food log revealed she was eating < 900 calories a

Julie Peck December 19, 2025 As GLP-1 receptor agonists move into wider use for diabetes and weight management, many primary care clinicians are discovering that prescribing the medication is only half the challenge. The other half lies in the conversation. The number of scripts for GLP-1 medications such as semaglutide and tirzepatide have surged. There

Marilynn Larkin December 08, 2025 Despite data suggesting that more than half of the patients (53.6%) discontinued GLP-1 drugs within a year, and 72.2% within 2 years, guidance on how to appropriately wean patients off the drugs, or perhaps convince them to continue taking them, is lacking. Faced with sparse evidence, clinicians find themselves relying on their

Edited by Archita Rai December 10, 2025   TOPLINE: Patients with type 2 diabetes who used tirzepatide had a 50% lower risk of developing primary open-angle glaucoma, a 41% lower risk of developing elevated eye pressure, and a 46% lower risk of initiating glaucoma treatments than those who used GLP-1 receptor agonists. METHODOLOGY: Researchers conducted a retrospective cohort study to

Heidi Splete December 03, 2025 Women with obesity who stopped taking GLP-1 receptor agonists (RAs) early in or before pregnancy gained seven more pounds than those who were never prescribed the weight-loss medications, according to a new observational study published in JAMA. These women also had a greater risk for adverse outcomes such as gestational diabetes, hypertensive disorders of